927 related articles for article (PubMed ID: 31553293)
1. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
2. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
4. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Jiang X; Li X; Li W; Bai H; Zhang Z
J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
[TBL] [Abstract][Full Text] [Related]
6. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
7. Update on PARP Inhibitors in Breast Cancer.
Zimmer AS; Gillard M; Lipkowitz S; Lee JM
Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
[TBL] [Abstract][Full Text] [Related]
8. A decade of clinical development of PARP inhibitors in perspective.
Mateo J; Lord CJ; Serra V; Tutt A; Balmaña J; Castroviejo-Bermejo M; Cruz C; Oaknin A; Kaye SB; de Bono JS
Ann Oncol; 2019 Sep; 30(9):1437-1447. PubMed ID: 31218365
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
11. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
12. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
13. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
Chen Y; Du H
Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
16. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
McCann KE
Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
20. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
